From the ∗Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, MA
†Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan
‡Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX
§Department of Radiation Oncology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston MA.
Received for publication May 9, 2022; accepted June 7, 2022.
Correspondence to: Mizuki Nishino, MD, MPH, Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (e-mail: [email protected]).
The authors declare no supported by R01CA203636, U01CA209414, R01HL111024, and R01CA240592. H.H. received research funding from Canon, Inc, Canon Medical Systems, and Konica-Minolta; Consultant to Canon Medical Systems, and Mitsubishi Chemical, Inc. M.N. served as a consultant to Daiichi Sankyo and AstraZeneca and received research grant from Merck, Canon Medical Systems, AstraZeneca, and Daiichi Sankyo. HM does consulting for Merck and received royalties from UpToDate. The other authors declare no conflict of interest.